Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ATHE vs ECOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECOR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

ECOR Overall Winner 6-Pillar Tally: ATHE 1 – 3 ECOR (2 Tie) Matrix Metrics: ATHE 3 – 5 ECOR

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ATHE carries a Unified Composite Score of 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin).

  • Technical & Structure Timing Caution: ATHE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATHE vs ECOR
ATHE NASDAQ
Alterity Therapeutics Limited American Depositary Shares
Pharmaceutical Preparations
$1.66
-2.65% 1D
Market Cap $32.5M
TTM Revenue $3.6M
Forward P/E N/M
Beta / 30D Vol 1.05β · 102% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.5%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $2.14 · SMA50: $2.83
ECOR NASDAQ Head-to-Head Winner
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67

6-Pillar Scorecard Institutional Category Breakdown (ATHE 1 – 3 ECOR)

Columns: Metric · ATHE · ECOR
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.0x 1.4x
2. Growth & Scale ECOR
Revenue Growth (YoY) -79.0% +11.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.6M $38M
Market Cap $32.5M $47.7M
3. Profitability & Quality ATHE
Gross Margin 92.7% 87.7%
Operating Margin -695.1% -33.1%
Net Profit Margin 0.0% -33.5%
Return on Equity (ROE) -55.0% -478.7%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$25M EBITDA -$6.9M
Cash Flow Margin N/A -18.1%
Net Cash / Leverage $1.65 Book/Sh · -55.0% ROE $4.6M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATHE (3) vs ECOR (5)
Institutional Metric ATHE ECOR Criterion Row Edge
Market Capitalization
Scale
$32.5M $47.7M Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-79.0% +11.5% Higher Growth ECOR
Operating Margin (TTM)
Profitability
-695.1% -33.1% Higher Margin ECOR
Net Profit Margin
Profitability
0.0% -33.5% Higher Margin ATHE
Return on Equity (ROE)
Capital Efficiency
-55.0% -478.7% Higher ROE ATHE
52-Week Range Position
Momentum
3% ($2–$6) 6% ($4–$13) Stronger Trend ECOR
Beta / 30D Volatility
Risk Regime
1.05β · 102% Vol 1.52β · 155% Vol Lower Realized Risk ATHE
Unified Institutional Score
Composite Signal
39.2 / 100 (SELL) 56.8 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$3.6M $38M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.7% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.0x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$25M EBITDA ($1.65 Book/Sh · -55.0% ROE) -$6.9M ($4.6M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATHE +3.26 pp
ATHE: -30.75% · ECOR: -34.01%
3M Horizon ECOR +10.66 pp
ATHE: -64.56% · ECOR: -53.9%
6M Horizon ECOR +41.38 pp
ATHE: -60.41% · ECOR: -19.03%
1Y Horizon ECOR +50.07 pp
ATHE: -54.03% · ECOR: -3.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHE vs ECOR. Trailing 12-month operating profitability (ATHE -695.1% vs ECOR -33.1%) and valuation multiples (ATHE N/M vs ECOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ATHE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.6M
Gross Margin92.7%
Op. Margin-695.1%
ROE / Fwd P/E-55.0% · N/M
ECOR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin87.7%
Op. Margin-33.1%
ROE / Fwd P/E-478.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATHE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATHE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATHE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $32.5M market capitalization and -695.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATHE vs ECOR Key Questions & Quantitative Answers

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Alterity Therapeutics Limited (ATHE) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ATHE carries a Unified Composite Score of 39.2/100 (SELL) at $1.66 (N/M Forward P/E, -695.1% operating margin), whereas ECOR carries 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin). Technical & Structure Timing Caution: ATHE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ATHE posts -79.0% YoY revenue growth and +0.0% YoY earnings growth on $3.6M TTM revenue (92.7% gross margin, -695.1% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). On trailing 12-month operating scale, ATHE generates $3.6M in USD-normalized revenue versus $38M for ECOR. In operating R&D and SG&A reinvestment, ATHE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.

ECOR screens cheaper on headline valuation multiples. ATHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.0x EV/Revenue (unreported EBITDA margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATHE (-55.0% ROE) versus ECOR (-478.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ATHE carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 102% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.